Boomerang Medical Raises $20 Million to Fund Neuromodulation Trial for Inflammatory Bowel Disease

Boomerang Medical, a California-based bioelectronic medicine company focused on women-led innovations, has raised $20 million in Series B funding. The capital will support the company’s pivotal BOOM-IBD2 trial, which explores the use of implantable neuromodulation devices to treat ulcerative colitis, a chronic autoimmune disease. The trial, which is enrolling patients at leading U.S. medical centers, marks the first time sacral neuromodulation will be evaluated for inflammatory bowel disease (IBD). Sacral neuromodulation, already used in other medical conditions, delivers gentle nerve stimulation through a small implanted device to reduce inflammation in the intestines.

The company previously conducted a feasibility study involving 40 patients with Crohn’s disease and ulcerative colitis. The results of that study informed the design of BOOM-IBD2. Ulcerative colitis, which affects millions in the U.S. and Europe, has no device-based treatments currently. Heather Simonsen, CEO of Boomerang Medical, emphasized the importance of the pivotal trial in determining if neuromodulation can reduce the debilitating symptoms of ulcerative colitis and improve quality of life.

The Crohn’s & Colitis Foundation recently recognized Boomerang as its “Emerging Leader in IBD,” marking the company as a significant innovator in this field. The trial is part of the company’s broader mission to bring new options to the IBD treatment landscape.